Inophos 400 mg Tablet Uses, Dosage, Side Effects and more

Attribute	Details
Trade Name	Inophos 400 mg Tablet
Generic	Sevelamer Hydrochloride
Weight	400 mg
Type	Tablet
Therapeutic Class	Drugs for reduction of serum phosphorus in patients with ESRD
Manufacturer	Incepta Pharmaceuticals Ltd.
Available Country	Bangladesh
Last Updated:	January 7, 2025 at 1:49 am

Uses

Inophos 400 mg Tablet is indicated for the reduction of serum phosphorus in patients with end-stage renal disease (ESRD).

Dosage

Patients not taking a Phosphate Binder: The recommended starting dose of Sevelamer is 800 to 1600 mg, which can be administered as two to four 400 mg Sevelamer tablets, with meals based on serum phosphorus level. Renophos 400 Recommendation for the patients with hyperphosphatemia is given below-Starting dose of Renophos for dialysis patients not taking any phosphate binder: Serum Phosphorus >5.5 and <7.5 mg/dL: 800 mg (2 tablets) three times daily with meals Serum Phosphorus ≥7.5 and <9.0 mg/dL: 1200 mg (3 tablets) three times daily with meals Serum Phosphorus ≥9.0 mg/dL: 1600 mg (4 tablets) three times daily with meals Starting dose for dialysis patients switching from calcium acetate to Sevelamer: Calcium Acetate 667 mg (1 tablet): Sevelamer 800 mg (2 tablets) Calcium Acetate 1334 mg (2 tablets): Sevelamer 1200 mg (3 tablets) Calcium Acetate 2001 mg (3 tablets): Sevelamer 2000 mg (5 tablets) Dose titration guideline: Serum Phosphorus >5.5 mg/dL: Increase 400 mg (1 tablet) per meal at 2 week intervals Serum Phosphorus 3.5-5.5 mg/dL: Maintain current dose Serum Phosphorus <3.5 mg/dL: Decrease 400 mg (1 tablet) per meal Dose titration for all patients taking Sevelamer: Dosage should be adjusted based on the serum phosphorus concentration with a goal of lowering serum phosphorus to 5.5 mg/dl or less. The dose may be increased or decreased by one tablet per meal at two week intervals as necessary.

Side Effects

Sevelamer may cause dyspepsia, peritonitis, diarrhea, nausea, constipation, pruritus, abdominal distension, vomiting, fatigue, anorexia, arthralgia and less commonly ileus, bowel obstruction and bowel perforation. See simplified version Inophos 400 mg Tablet also Inophos 400 mg Tablet in bangla

Precaution

The safety and efficacy of Sevelamer in patients with dysphagia, swallowing disorders, severe GI motility disorders including severe constipation, or major GI tract surgery have not been established. Caution should be exercised when Sevelamer is used in patients with these GI disorders.

Interaction

Sevelamer has been studied in human drug-drug interaction studies with ciprofloxacin, digoxin, warfarin, enalapril, metoprolol and iron.

Pregnancy & Breastfeeding use

Pregnancy Category C. No adequate and controlled studies have been conducted using Sevelamer in nursing mothers. Sevelamer should be used during breastfeeding only if the potential benefit justifies the potential risks.

Contraindication

Sevelamer is contraindicated in patients with hypophosphatemia or bowel obstruction and in patients with known hypersensitivity to Sevelamer hydrochloride or any of its constituents.